ESH How to Diagnose and Treat conferences are disease-specific meetings that address state-of-the-art diagnostic and clinical management.
The ESH 5th How to Diagnose and Treat Multiple Myeloma conference aims to present and debate the latest data and information in the field of Multiple Myeloma. This thought-provoking academic dialogue will address the most challenging current biology, clinical and therapeutic questions. The unique format of the programme, including case-based presentations, debates and round tables provides a unique platform for discussion.
The meeting will provide clinicians and scientists with state-of-the-art recommendations regarding patient care and insight in controversies in the field.
This conference will bring together a distinguished assembly of leading scientists, clinicians, and healthcare professionals from around the globe in the heart of Vienna. This annual meeting provides a unique and essential platform for sharing cutting-edge research and clinical advances in the field of multiple myeloma.
In recent years, understanding the clinical course and treatment of multiple myeloma has witnessed remarkable progress, with breakthroughs in molecular biology, genomics, and immunotherapy offering new avenues for more effective and personalized treatments. During this meeting, we will explore these advancements, engage in critical discussions on emerging therapeutic strategies, and examine their potential to reshape the clinical landscape. From early detection and disease monitoring to novel drug developments and the latest in immunomodulatory approaches, the ESH Myeloma Meeting 2025 is designed to facilitate comprehensive dialogue among experts at the forefront of hematologic research.
Continuing Medical Education (CME) credit points will be awarded to physicians for the time they will spend at the meeting improving their knowledge and skills. ESH is a provider of the European Hematology CME system.
Posters and Brief Oral Communications:
Registered participants are invited to submit their Clinical Cases and abstracts. Selected Clinical Cases and abstracts will be presented as brief oral communications or posters.
Call for abstracts: deadline January 30, 2025
This meeting will be valuable to you if you are looking for:
• A cutting-edge scientific programme – from basic science to clinical and therapeutic applications and perspectives
• Multiple opportunities for scientific interaction with an international faculty of distinguished experts
• An emphasis on critical discussion
The meeting will provide clinicians and scientists with state-of-the-art recommendations regarding patient care and insight in controversies in the field.
The meeting will be of interest to:
• Senior biologists and clinicians, including experts in the field (MD, PhD, MD-PhD)
• Junior scientists and clinicians (MD, PhD)
• PhD candidates and clinical residents still in-training
Learning Objectives:
- Update on the diagnosis and profiling of myeloma
- Upfront treatment of transplant eligible and non-eligible myeloma patients
- Treatment of relapsed myeloma patients
- Risk-adapted therapy
- Immune therapy
- Diagnosis and treatment of plasma cell dyscrasias other than multiple myeloma
Scientific Topics:
– How I treat smoldering myeloma (SMM)
– How I treat newly diagnosed multiple myeloma
– From risk stratification to risk-based therapy?
– Should we use MRD testing to determine therapy in multiple myeloma?
– Is CAR T cell therapy replacing autologous SCT?
– How I treat relapsed multiple myeloma
– Cell free DNA / circulating tumor cells to replace BM-biopsy and MRD measurement
– You can’t be immune for immune therapy anymore
– The future of multiple myeloma
– Other plasma cell dyscrasias
The programme will include:
– Plenary Sessions
– Interactive Case Presentations
– Roundtables
– Panel Discussions
– Debates
– Poster Walks
– Meet the Expert Sessions
– Voting technology
To register for the event follow the link here: https://www.esh.org/conference/5th-how-to-diagnose-and-treat-multiple-myeloma/
For any queries please email the following address: [email protected]
